Alphagan 0.20 Eye Drop
    Alphagan 0.20 Eye Drop
    Alphagan 0.20 Eye Drop

    Alphagan 0.20 Eye Drop

    ☆☆☆☆☆
    (0 customer reviews)
    Price range: $35.41 through $96.91
    Whatsapp

    In Stock

    Alphagan 0.20 Eye Drop
    1 / 3
    Product image 1
    Product image 2
    Product image 3

    Alphagan 0.20 Eye Drop

    Price range: $35.41 through $96.91
    In Stock
    Secure
    Checkout
    Free
    Shipping
    30-Day
    Returns
    Quality
    Guaranteed
    Quantity
    Safe Payment

    All major cards & wallets accepted

    Premium Quality

    Tested to highest standards

    24/7 Support

    We're here whenever you need us

    Money-Back Guarantee

    30-day no questions asked

    What Is Alphagan 0.20 Eye Drop?

    Alphagan 0.20 Eye Drop is a sterile, preserved, aqueous ophthalmic solution containing Brimonidine Tartrate 0.2% (2 mg/ml) in a buffered solution preserved with benzalkonium chloride (BAK). It is the original Allergan Brimonidine formulation — the benchmark against which all newer Brimonidine preparations (including Alphagan P 0.15% and 0.1%) have been clinically compared in equivalence trials. The 0.2% strength provides robust IOP reduction of 2 to 6 mmHg from baseline — a clinically meaningful reduction that materially slows glaucomatous optic nerve damage progression. Unlike beta-blocker-based IOP-lowering drops (such as Timolol), Brimonidine works through the alpha-2 adrenergic receptor pathway — making Alphagan 0.20 a critical treatment option for patients with asthma, reactive airways disease, bradycardia, or heart failure who cannot safely use topical beta-blockers. It can also be used as an adjunct to other IOP-lowering drops when monotherapy is insufficient to reach target pressure. Patients looking to compare glaucoma eye drop options across different drug classes can explore the eye care products collection at Ed Care Store, which covers multiple anti-glaucoma and ophthalmic product categories.

    What Is Alphagan 0.20 Eye Drop Used For?

    Open-Angle Glaucoma (OAG) – Primary Indication

    Open-angle glaucoma is the most prevalent form of glaucoma globally, accounting for over 70% of all glaucoma cases. It develops when the trabecular meshwork — the eye's primary aqueous drainage structure — becomes progressively obstructed, reducing outflow and causing IOP to rise. Since the optic nerve is under constant elevated pressure stress, ganglion cell axons are progressively lost, producing characteristic visual field defects that begin in the peripheral field and advance centrally over years to decades. Alphagan 0.20 is prescribed as both monotherapy and adjunctive therapy in open-angle glaucoma. As monotherapy, it is particularly valuable for patients who cannot use topical beta-blockers. As adjunctive therapy, it provides additional IOP reduction in patients already using a prostaglandin analogue, beta-blocker, or carbonic anhydrase inhibitor whose IOP remains above target despite maximum tolerated monotherapy dosing.

    Ocular Hypertension (OHT)

    Ocular hypertension is defined as IOP consistently above 21 mmHg without detectable optic nerve damage or visual field loss at the time of diagnosis. While not all patients with OHT progress to glaucoma, the Ocular Hypertension Treatment Study (OHTS) demonstrated that IOP-lowering therapy significantly reduces the risk of conversion. Alphagan 0.20 effectively lowers IOP in OHT, protecting the optic nerve from future pressure-related injury before irreversible damage begins.

    Post-Laser Trabeculoplasty IOP Spike Prevention

    Alphagan 0.20 is also used perioperatively to prevent acute IOP spikes following argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT) — procedures used to improve trabecular meshwork drainage in glaucoma patients. A single dose of Brimonidine administered one hour before the procedure significantly attenuates the post-laser IOP elevation that can temporarily endanger the optic nerve. Patients who also require a dual-mechanism combination drop for more aggressive IOP control can explore Dorzox T 5 Ml Eye Drop (Dorzolamide + Timolol) — a beta-blocker + carbonic anhydrase inhibitor combination — available as an adjunct option on the same platform.

    How Does Alphagan 0.20 Eye Drop Work?

    Dual Mechanism of Action – A Unique IOP-Lowering Profile

    Brimonidine Tartrate is a highly selective alpha-2 adrenergic receptor agonist — meaning it preferentially activates alpha-2 receptors over alpha-1 receptors, which accounts for its favourable ocular and systemic tolerability profile. Its IOP-lowering effect operates through two complementary, simultaneous mechanisms:
    • Reduction of Aqueous Humour Production (Primary Mechanism): Alpha-2 receptors are expressed on the non-pigmented ciliary epithelium — the tissue responsible for actively secreting aqueous humour into the posterior chamber. Brimonidine's activation of these receptors suppresses adenylyl cyclase, reducing intracellular cAMP and directly inhibiting the active secretion of aqueous humour. Less fluid produced = lower IOP.
    • Enhancement of Uveoscleral Outflow (Secondary Mechanism): Brimonidine also activates alpha-2 receptors in the ciliary muscle and uveal tissue, which promotes increased drainage of aqueous humour through the uveoscleral (non-trabecular) outflow pathway — a secondary drainage route that bypasses the obstructed trabecular meshwork. This provides a complementary pressure-reducing effect independent of the secretion-inhibition pathway.
      This dual mechanism is what distinguishes Brimonidine from both beta-blockers (which only reduce aqueous production via a cAMP pathway) and prostaglandin analogues (which only enhance uveoscleral outflow). Brimonidine achieves meaningful reductions through both pathways simultaneously — providing a pharmacologically comprehensive IOP reduction that makes it effective even in patients who have partial resistance to single-mechanism agents.

    Potential Neuroprotective Effect – Beyond IOP Reduction

    A clinically important and distinctive property of Brimonidine is its growing evidence base for direct optic nerve neuroprotection — independent of IOP reduction. Laboratory studies demonstrate that Brimonidine activates alpha-2 receptors on retinal ganglion cells, stimulating anti-apoptotic signalling pathways (PI3K/Akt, ERK) that protect ganglion cells from ischaemic, excitotoxic, and oxidative stress. Brimonidine has also been shown to reduce glutamate accumulation in the vitreous — preventing glutamate excitotoxicity that contributes to retinal ganglion cell death in glaucoma independent of IOP. This potential neuroprotective profile makes Alphagan 0.20 particularly attractive for patients with normal-tension glaucoma (NTG) — a form of glaucoma where optic nerve damage progresses despite IOP levels within the statistically normal range (under 21 mmHg), suggesting non-pressure vascular and ischaemic mechanisms contribute significantly to optic nerve injury. For patients who also use Bimatoprost-based drops for IOP management, Careprost Eye Drops (Bimatoprost 0.03%) — a prostaglandin analogue that enhances aqueous outflow — is available on the same platform and can be combined with Alphagan 0.20 under physician guidance for enhanced pressure reduction.

    How to Use Alphagan 0.20 Eye Drop Correctly

    Correct instillation technique maximises ocular drug delivery and minimises systemic absorption through the nasolacrimal drainage system:
    • Wash hands thoroughly before handling the bottle or touching around the eye.
    • Contact lens removal: Remove soft contact lenses before instillation. The benzalkonium chloride preservative in Alphagan 0.20 is absorbed by soft lenses and can cause ocular irritation. Wait at least 15 minutes before reinserting lenses.
    • Tilt head back and look upward. Pull down the lower eyelid with one finger to form a small conjunctival pocket.
    • Instil one drop into the conjunctival pocket. Hold the tip close to the eye but do not allow the dropper tip to touch the eye, eyelid, eyelashes, or any other surface.
    • Nasolacrimal occlusion — critical step: Immediately press the inner corner of the eye (the nasal canthus, where the tear duct opens) firmly with your fingertip for 1 to 2 full minutes. This substantially reduces the drainage of Brimonidine through the nasolacrimal duct into the nasal passage and systemic circulation — preventing central nervous system depression, cardiovascular effects, and dry mouth.
    • Close the eye gently and keep it closed for 1–2 minutes without blinking vigorously.
    • Wipe away excess solution around the eye with a clean tissue.
    • Multiple eye drops: If using other ophthalmic medications, wait at least 5 minutes between each product.
    • Dosing schedule: Apply one drop three times daily, approximately 8 hours apart (e.g., 7 AM, 3 PM, 11 PM) — consistent timing is essential for continuous IOP control.
    • Replace the cap tightly after every use to maintain sterility.
     

    Alphagan 0.20 Eye Drop Dosage Guidelines

    Indication Dose Frequency Interval Notes
    Open-Angle Glaucoma (adults) 1 drop in affected eye(s) 3 times daily ~8 hours apart Consistent daily schedule essential
    Ocular Hypertension (adults) 1 drop in affected eye(s) 3 times daily ~8 hours apart Continue even when symptoms absent
    Post-Laser Trabeculoplasty 1 drop in affected eye(s) Pre-procedure dose 1 hour before laser Prevents acute IOP spike
    Adjunct therapy 1 drop in affected eye(s) 3 times daily ~8 hours apart 5-min gap from other drops
    Children ≥2 years 1 drop as prescribed As directed by ophthalmologist ~8 hours apart Use with caution; monitor closely
      Important: Do not skip doses — consistent three-times-daily use is necessary to maintain stable 24-hour IOP control. A missed dose should be taken as soon as remembered, unless it is close to the time of the next scheduled dose. Never double dose. Alphagan 0.20 controls IOP but does not cure glaucoma — long-term, uninterrupted daily therapy is required throughout the course of the disease. Patients managing dry eye discomfort alongside glaucoma drops — a common combination since BAK-preserved drops can reduce tear film stability — can explore Trehalube Eye Drop 10 Ml (Sodium Hyaluronate + Trehalose) — a preservative-free lubricant available on the same platform, applied at least 5 minutes after Alphagan 0.20.

    Key Benefits of Alphagan 0.20 Eye Drop

    • Dual-Mechanism IOP Reduction: Reduces aqueous production AND enhances uveoscleral outflow simultaneously — a pharmacologically complete approach that other single-mechanism agents (beta-blockers or prostaglandins alone) cannot match.
    • Safe Alternative to Beta-Blockers: Alphagan 0.20 is specifically indicated for patients who cannot use Timolol or other beta-blockers due to asthma, COPD, bradycardia, or heart failure — an important clinical niche for a large subset of glaucoma patients.
    • Clinically Proven 2–6 mmHg IOP Reduction: Achieves statistically and clinically significant IOP lowering from baseline — directly translating to a reduced rate of optic nerve damage progression and visual field loss.
    • Potential Direct Neuroprotection: Emerging and laboratory evidence supports a direct retinal ganglion cell protective effect of Brimonidine beyond IOP reduction — particularly relevant for normal-tension glaucoma patients.
    • Excellent Adjunct Compatibility: Alphagan 0.20 can be combined with all major classes of IOP-lowering drops (prostaglandins, beta-blockers, CAIs) when monotherapy is insufficient — with 5-minute spacing between different drops.
    • Three-Times-Daily Dosing – No Overnight Pressure Gap: Unlike once-daily prostaglandin analogues whose IOP effect varies across 24 hours, Alphagan 0.20's three-daily dosing provides more consistent IOP control throughout the full 24-hour cycle when adherence is maintained.
    • Allergan Originator Quality: Alphagan is the original branded Brimonidine formulation from Allergan (now part of AbbVie) — manufactured to the most rigorous pharmaceutical quality standards with decades of global safety and efficacy data.
    • Perioperative IOP Protection: Used pre-operatively before laser trabeculoplasty to blunt post-laser IOP spikes — a well-established, guideline-supported clinical application.
      Patients managing age-related macular conditions alongside glaucoma can also support their retinal health with oral nutritional supplementation. Macuchek Forte Capsule (Lutein, Zeaxanthin, Astaxanthin, Omega-3) is available on the same platform for comprehensive macular antioxidant nutrition.

    Common Side Effects of Alphagan 0.20 Eye Drop

    Ocular Side Effects (Most Common)

    • Allergic conjunctivitis: Reported in 10–20% of patients on long-term Brimonidine therapy — manifesting as itching, redness, conjunctival follicles, and eyelid oedema. This is the most clinically significant tolerability issue with Alphagan 0.20 and often necessitates switching to the lower-concentration Alphagan P formulation or a different drug class
    • Conjunctival hyperaemia (redness): Common, usually mild and transient
    • Burning or stinging sensation upon instillation
    • Conjunctival folliculosis: Formation of small lymphoid follicles on the tarsal conjunctiva; typically asymptomatic
    • Blurred or disturbed vision immediately after instillation: Resolves quickly; avoid driving until fully cleared
    • Ocular pruritus (itching)
    • Eyelid erythema or periorbital dermatitis
    • Dry eye or keratoconjunctivitis sicca: BAK preservative may reduce tear film stability with prolonged use
     

    Systemic Side Effects (Due to Nasolacrimal Absorption — Reduced by Punctal Occlusion)

    • Dry mouth (xerostomia): Most common systemic anticholinergic-like effect; reduced by nasolacrimal occlusion after instillation
    • Drowsiness and fatigue: Alpha-2 CNS activation can cause mild sedation — particularly relevant in elderly patients and those driving
    • Headache
    • Hypotension: Mild blood pressure reduction; caution in patients with existing low BP or on antihypertensives
    • Oral dryness and bitter taste
    • Depression or mood changes: Rare but reported; caution in patients with history of depression
    • Bradycardia: Rare; more clinically relevant in patients with pre-existing cardiovascular disease
      Serious but rare: syncope (fainting), iritis, respiratory depression (particularly in infants — Alphagan 0.20 is absolutely contraindicated under age 2). Discontinue and contact your ophthalmologist if persistent ocular allergy or systemic symptoms develop.

    Who Should Not Use Alphagan 0.20 Eye Drop?

    • Neonates and infants under 2 years of age — absolute contraindication. Systemic Brimonidine causes severe CNS depression, apnoea, bradycardia, and hypotension in infants; cases of coma have been reported
    • Patients receiving MAO inhibitor (MAOI) therapy: Absolute contraindication — dangerous hypertensive and other pharmacodynamic interactions. Do not use within 14 days of any MAOI
    • Patients with known hypersensitivity to Brimonidine Tartrate or any excipient including benzalkonium chloride
    • Patients receiving tricyclic antidepressants: May potentiate cardiovascular effects and alter Brimonidine metabolism
      Use with special caution in: patients with depression (Brimonidine has CNS alpha-2 activity that may worsen mood), severe cardiovascular disease, Raynaud's phenomenon, orthostatic hypotension, cerebrovascular or coronary insufficiency, hepatic or renal impairment (clearance reduced), children aged 2–7 years (heightened CNS sensitivity), and patients on antihypertensive medications (additive BP lowering). Pregnancy: Category B — use only when benefit outweighs risk. Brimonidine crosses the placenta. Breastfeeding: Not recommended — Brimonidine has been shown in animal studies to be excreted into breast milk and may cause serious adverse effects in nursing infants. For patients using Loteprednol-based eye ointment alongside Alphagan 0.20 for co-existing anterior segment inflammation, Lotel Eye Ointment 5 Gm (Loteprednol Etabonate) — with its reduced IOP-elevating risk compared to conventional steroids — is available on the same platform.

    Key Drug Interactions

    Interacting Drug / Class Risk of Interaction Clinical Action Required
    MAO Inhibitors (phenelzine, tranylcypromine, isocarboxazid, selegiline, linezolid) ABSOLUTE contraindication — severe hypertensive reaction and other dangerous pharmacodynamic interactions Do not use — stop MAOIs at least 14 days before starting Alphagan 0.20
    Tricyclic Antidepressants (amitriptyline, imipramine, clomipramine) May blunt or alter Brimonidine's IOP-lowering effect and cause cardiovascular interactions Use with caution; consider alternative IOP-lowering therapy
    CNS Depressants (opioids, benzodiazepines, barbiturates, alcohol, anaesthetics) Additive CNS depression — sedation, impaired cognition, reduced alertness Avoid combination or use with caution; warn patients about impaired driving
    Antihypertensives (beta-blockers, calcium channel blockers, ACE inhibitors) Additive blood pressure reduction — hypotension, dizziness, syncope risk Monitor blood pressure regularly; adjust antihypertensive doses if needed
    Cardiac Glycosides (digoxin) Additive potential for bradycardia and cardiovascular depression Monitor heart rate; caution in patients with borderline cardiac function
    Other Topical IOP-Lowering Drops (any class) Additive IOP-lowering beneficial — no harmful pharmacodynamic interaction Maintain 5-minute interval between different ophthalmic products
    Mifepristone Potential reduced Brimonidine IOP-lowering efficacy Avoid concurrent use where possible
     

    Alphagan 0.20 vs Other IOP-Lowering Drops — Clinical Comparison

    Feature Alphagan 0.20 (Brimonidine) Dorzox T (Dorz./Timolol) Careprost (Bimatoprost) Bimat (Bimatoprost)
    Drug Class Alpha-2 Agonist CAI + Beta-Blocker Prostaglandin Analogue Prostaglandin Analogue
    Mechanism Reduces production + uveosc. outflow Reduces production (dual) Enhances trabecular + uveoscleral outflow Enhances trabecular + uveoscleral outflow
    IOP Reduction 2–6 mmHg ~30–35% ~25–33% ~25–33%
    Dosing Frequency 3x daily (~8 hrs apart) Twice daily Once daily (evening) Once daily (evening)
    Beta-Blocker Risk ✓ None — safe in asthma/COPD ⚠ Timolol contraindicated in asthma ✓ None ✓ None
    Neuroprotective Evidence ✓ Growing evidence ✗ None known ✗ None known ✗ None known
    MAOI Interaction Risk ⚠ Absolute contraindication ✗ No ✗ No ✗ No
    Manufacturer Allergan (AbbVie) Sun Pharma Sun Pharma Ajanta Pharma
      Patients who require a Bimatoprost-based option — particularly those interested in the concurrent eyelash-growth side effect of Bimatoprost — can also explore Bimat Eye Drops (Bimatoprost) on the same platform as an alternative or adjunct prostaglandin analogue option.

    Storage Instructions for Alphagan 0.20 Eye Drop

    • Store between 15°C and 25°C (59°F to 77°F) — at room temperature in a cool, dry location
    • Protect from direct sunlight and heat sources
    • Keep the bottle cap tightly closed between uses to maintain sterility
    • Do not refrigerate or freeze
    • Keep out of reach of children and pets — Brimonidine is particularly dangerous for infants
    • Discard the bottle 28 days after first opening regardless of remaining content — multi-dose bottles can become microbiologically contaminated
    • Do not use if the solution changes colour or becomes cloudy — discard and obtain a replacement
    • Check the expiry date on the bottle and carton before every use
     

    Why Order Alphagan 0.20 Eye Drop from Ed Care Store?

    Ed Care Store (edcarestore.com) is a trusted online healthcare pharmacy providing quality-assured ophthalmic, respiratory, and general health medicines with complete discretion and competitive pricing. When you purchase Alphagan 0.20 Eye Drop through Ed Care Store, here is what sets the experience apart:
    • Authentic Allergan (AbbVie) Products: Alphagan 0.20 Eye Drop is sourced from verified, licensed supply channels — every bottle is genuine Allergan-manufactured, sterile, and GMP-quality-assured.
    • Discreet, Tamper-Evident Delivery: All orders are dispatched in plain, secure packaging — your health information and privacy are fully protected at every stage.
    • Competitive Pricing on Originator Brand: Access to the original Allergan Brimonidine formulation at accessible pricing — making long-term glaucoma management affordable without switching to generic alternatives.
    • Complete Eye Care Range: Beyond Alphagan 0.20, explore the full range of anti-glaucoma and eye care products — including lubricants, ICS eye ointments, nutritional supplements, and combination IOP drops — all in one trusted platform.
    • Men's Health Products Available: Men managing concurrent conditions alongside glaucoma can also access the complete men's health range — including trusted ED solutions — through the same platform.
    • Informative Health Content: Visit the Ed Care Store health blog for informational content on eye health, glaucoma management strategies, and general wellness topics.
    Glaucoma is irreversible — but with consistent, correctly applied IOP-lowering therapy, its progression can be slowed dramatically. Alphagan 0.20 Eye Drop delivers the dual-mechanism, clinically proven Brimonidine pressure reduction that patients with open-angle glaucoma and ocular hypertension need, backed by over two decades of global clinical use and Allergan's originator manufacturing standards. Order through Ed Care Store for genuine product, complete privacy, and the confidence that your glaucoma management is in reliable hands. Disclaimer: The information on this page is for educational purposes only and does not substitute professional ophthalmic or medical advice, diagnosis, or treatment. Alphagan 0.20 Eye Drop is a prescription-only medicine. Always consult a qualified ophthalmologist before starting, adjusting, or stopping any glaucoma medication. Alphagan 0.20 is absolutely contraindicated in children under 2 years of age and in patients receiving MAO inhibitors. Ed Care Store stocks products exclusively from verified, licensed pharmaceutical manufacturers.
    Alphagan 0.20 Eye Drop 3 Bottle, 6 Bottle, 9 Bottle
    We offer free standard shipping on all orders. Orders are processed within 1-2 business days and typically arrive within 5-7 business days.
    We accept returns within 30 days of purchase. Items must be in original condition with tags attached.
    Yes! All our products come with a comprehensive warranty against defects in materials or workmanship.
    Alphagan 0.20 Eye Drop
    $35.41 – $96.91Price range: $35.41 through $96.91
    Product zoom
    EdCareStore Footer Image

    Address
    5954 Old Cove Heath Rd Eupora, Mississippi(MS), 39744

    US Call/Text
    +1 (914) 999-2631

    Email
    support@edcarestore.com

    Trending Products

    Vardenafil

    Blue Pill

    Tadalafil

    Oral ED Jelly

    Bimatoprost

    Shop by category

    Shop All

    Men’s Health

    Women’s Health

    Eye Care

    Asthma

    Diabetes

    Company

    About Us

    Reviews

    Medicine Policy

    Shipping Policy

    Communication Policy

    Disclaimer Policy

    User guide

    Indian Pharmacies

    Protect Yourself

    Regulated Medicine

    Returns & Exchanges

    Safe and Secure Shopping

    FAQs

    Most Searches

    Cenforce 200 mg | Viagra | Vidalista | Sildenafil | Cenforce | Cenforce 120 Mg | Visalista 60 Mg 

    Copyright © 2026 Edcarestore | All Rights Reserved

    Request Your Free Sample

    Fill out the form below and our pharmacist will get in touch!

    Please select an option
    Full name is required
    Valid phone number is required
    Valid email address is required
    Please describe the sample you're looking for

    Thank You!

    Your free sample request has been received.

    Due to high demand, our pharmacist will reach out to you within the next 3-4 business days.